Karen Silence

Scientific Advisor

Karen Silence worked for four years at the University of Brussels developing the Nanobody platform which lead to the establishment of Ablynx, where she was the first employee. Karen was also inventor and project leader for Caplacizumab, the first and only Nanobody approved today.


After that Karen joined argenx where she was inventor and project leader for ARGX-110, ARGX-117, ARGX-119 and ARGX-120.


Karen has since worked 6 years as an independent consultant and supported argenx, Citryll, Catalym and Staten with the preclinical development of their antibodies.


At this moment Karen is head of all late stage discovery programs at argenx as a consultant. Karen’s expertise is in antibody optimization and engineering, CMC, bioanalytics.

This site uses cookies to provide you with a great user experience. By using our website, you accept our use of cookies.